Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast

The Stock Day Podcast welcomed Acasti Pharma, Inc. (Nasdaq:ACST), a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. CEO of the Company, Jan D’Alvise, joined Stock Day host Everett Jolly.